MREO
Mereo BioPharma Group (MREO)
$10
About Mereo BioPharma Group (MREO)
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.
Details
Daily high
$2.19
Daily low
$2.10
Price at open
--
52 Week High
$3.88
52 Week Low
$1.47
Market cap
334.1M
Dividend yield
0.00%
Volume
1
Avg. volume
2.3M
P/E ratio
-7.97
Mereo BioPharma Group News
Details
Daily high
$2.19
Daily low
$2.10
Price at open
--
52 Week High
$3.88
52 Week Low
$1.47
Market cap
334.1M
Dividend yield
0.00%
Volume
1
Avg. volume
2.3M
P/E ratio
-7.97